Aeluma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022. The request metadata says “2021 Q4,” but the filing is an annual report for fiscal 2022; its reported periods include a six-month transition period ended June 30, 2021, following a change in fiscal year-end.
Business context
Aeluma is an early-stage optoelectronics company developing compound-semiconductor devices integrated on large-diameter silicon wafers, targeting imaging, LiDAR, 3D sensing, communications, and related markets. It remains in research and development, has no commercial products or customers, and reported no revenue. The June 2021 reverse merger brought Biond Photonics’ operations into the public company; Biond is the accounting acquirer.
Key financial metrics
| Metric | Fiscal year ended June 30, 2022 |
|---|---|
| Revenue | $0 |
| Operating expenses | $3.734 million, including $1.064 million R&D, $1.907 million general and administrative, $436,000 facility, and $327,000 insurance |
| Other income | $282,000, primarily sublease rental and other income |
| Net loss | $3.452 million; basic and diluted loss per share was $0.32 |
| Operating cash flow | $(2.253) million |
| Investing cash flow | $(956,000), primarily facility setup and equipment |
| Financing cash flow | $162,000 net |
| Cash | $3.741 million at June 30, 2022, down from $6.787 million a year earlier |
| Liquidity | Current assets $4.431 million; current liabilities $372,000; reported working capital $4.058 million |
| Debt and lease obligations | No notes payable outstanding; operating lease liability totaled $616,000, including $157,000 current |
| Total assets and liabilities | Assets $5.931 million; liabilities $831,000 |
Margins are not meaningful because the company had no revenue. The balance sheet reports accumulated deficit of $3.682 million, while the MD&A and note disclosure state $3.586 million; the filing text does not provide a clear reconciliation.
Changes versus prior periods
Operating expenses and net loss increased substantially as the company started operations, expanded R&D and facility activity, and recorded stock-based compensation. Net loss was $217,000 for the six months ended June 30, 2021 and $13,000 for calendar 2020. These are not directly comparable full-year periods. Cash declined by $3.047 million during fiscal 2022, while current assets fell from $7.472 million to $4.431 million. The company raised $206,930 net from a private placement during fiscal 2022.
Outlook, risks, and unusual items
- Management expects significant additional spending before positive operating cash flows and says current funds are insufficient to complete its business plan. It plans to seek financing, control expenses, and pursue material sales or research contracts, but had no formal agreements for these measures as of the report date.
- The auditor’s report and management disclosure state that recurring losses, negative operating cash flows, and no revenue raise substantial doubt about the company’s ability to continue as a going concern. Additional financing is not assured and may dilute shareholders or impose restrictive terms.
- COVID-related supplier disruption, extended equipment and materials lead times, and difficulty scheduling equipment support affected development planning. The filing also identifies risks from competition, commercialization and manufacturing execution, export controls, and dependence on external manufacturing partners.
- Disclosure controls and internal control over financial reporting were deemed ineffective at June 30, 2022, attributed to insufficient personnel with technical accounting and SEC reporting expertise. The auditor did not attest to internal control effectiveness.
- Stock-based compensation was a notable expense: $204,000 for options in fiscal 2022, with $1.018 million of unrecognized option compensation at year-end. The company also amortized $662,000 of deferred compensation related to restricted stock awards.
- No material litigation was reported as pending. No cash dividends are anticipated in the foreseeable future. No specific revenue, product-launch, or profitability guidance was provided.
Important facts for investors to verify
- Resolve the accumulated-deficit discrepancy between the balance sheet and MD&A/note disclosure.
- Assess cash runway, likely funding needs, and whether the company can obtain financing on acceptable terms.
- Track evidence of customer commitments, research contracts, prototypes, and progress toward commercial manufacturing.
- Monitor remediation of the disclosed material weakness and improvement in financial reporting controls.
- Review dilution exposure from outstanding options, warrants, and the equity incentive plan, as well as the terms of the facility lease.